Biotech Values

[DonShimoda]

XOMA - Competition
**note The results from XOMA's PoC P2 trial in Acne Vulgaris are expected in early 2013.

XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
Safety of True Human(TM) Monoclonal Antibody Therapy Enables Development of First Biologic Treatment Targeting Inflammatory Cytokine IL-1a for Moderate to Severe Acne

AUSTIN, Texas, Dec. 12, 2012 /PRNewswire via COMTEX/ -- XBiotech Inc., a privately held biotechnology company, today announced positive Phase II clinical trial results in the treatment of acne vulgaris. The trial was conducted as an open label study using XBiotech's lead candidate, True Human(TM) monoclonal antibody MABp1, in patients with moderate to severe disease. Patients enrolled in the study demonstrated continual improvement in lesions over the course of therapy, with up to 42 percent reduction in eight weeks. The excellent safety profile of MABp1 demonstrated across multiple therapeutic indications to date, and strong initial results in this trial, provide the basis for further development of the first biologic therapy targeting the inflammatory cytokine IL-1a for acne treatment.


Acne vulgaris is a common skin disease that affects an estimated 80% of Americans at some time during their lives. Twenty percent will have severe acne, which results in permanent physical and mental scarring. Acne vulgaris is America's most common skin disease and is characterized by non-inflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules.

Currently, there are several approved topical and systemic treatments however no biological therapy has yet been approved for the treatment of acne. The Phase II clinical trial involving the XBiotech proprietary platform technology was a multicenter study, and included leading investigators such as Dr. Ronald Moy, recent President of the American Academy of Dermatology, former Co-Chief of Dermatology, and Chief of Dermatological Surgery at UCLA Medical Center.
http://www.marketwatch.com/story/xbiotech-announces-positive-phase-ii-clinical-trial-results-for-lead-candidate-mabp1-in-acne-vulgaris-2012-12-12